MicroRNA encapsulated nanocells (EnGeneIC) |
|
Phase 2 Clinical |
Engeneic |
Mesothelioma |
Details
|
Recombinant human anti-EGFR mAB (Genrix Bio) |
GR-1401; UBP-1215 |
Phase 1 Clinical |
Shanghai Zhonghe Medicine Technology Co Ltd, Bioex Therapeutics |
Head and Neck Neoplasms; Solid tumours; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Cetuximab biosimilar (R-Pharm) |
RPH-002 |
Phase 3 Clinical |
R-Pharm |
Head and Neck Neoplasms; Pancreatic Neoplasms |
Details
|
D2C7-based immunotoxins (Duke University) |
D2C7-IT; scds-D2C7 -PE38KDEL; D2C7-(scdsFv)-PE38 KDEL |
Phase 1 Clinical |
Istari Oncology, Duke University |
Glioma |
Details
|
Nimotuzumab biosimilar (El Kendi Pharmaceuticals Manufacturing) |
|
Phase 3 Clinical |
El Kendi Pharmaceuticals |
Uterine Cervical Neoplasms |
Details
|
WSD-0922 |
WSD0922; WSD-0922 |
Phase 1 Clinical |
Vision Biological Tech (Hefei) Co Ltd |
Glioblastoma; Glioma |
Details
|
MCLA-129 |
MCLA-129 |
Phase 2 Clinical |
Merus |
Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
XZP-5809-TT1 |
XZP-5809-TT1; XZP-5809 |
Phase 2 Clinical |
Shandong Xuanzhu Pharmaceutical Technology Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
Puvitinib |
|
Phase 1 Clinical |
Suzhou Teligene Ltd |
Solid tumours |
Details
|
ASP-0598 |
ASP-0598 |
Phase 2 Clinical |
Auration Biotech, Astellas Pharma Inc |
Ear Diseases; Tympanic Membrane Perforation |
Details
|
CM-93 |
CM-93 |
Phase 1 Clinical |
Shanghai Crimson Pharmaceutical Co Ltd |
Glioblastoma |
Details
|
Zorifertinib |
AZD-3759 |
Phase 3 Clinical |
Astrazeneca Plc |
Brain metastases; Carcinoma, Non-Small-Cell Lung |
Details
|
Depatuxizumab mafodotin |
ABT-414; ABT-414/806 |
Phase 3 Clinical |
Abbvie Inc |
Glioblastoma; Gliosarcoma; Carcinoma, Squamous Cell; Glioma; Carcinoma, Non-Small-Cell Lung |
Details
|
Anti-EGFR-IL-dox (Swiss Group for Clinical Cancer Research) |
|
Phase 2 Clinical |
Schweizerische Arbeitsgemeinschaft Für Klinische Krebsforschung |
Breast Neoplasms |
Details
|
AMX-3009 Maleate |
AMX-3009; AMX3009马来酸 |
Phase 1 Clinical |
Anrun Medicine Technology (Suzhou) Co Ltd |
Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms |
Details
|
SGT-210 |
SGT-210 |
Phase 1 Clinical |
Sol Gel Technologies Pte Ltd |
Keratosis |
Details
|
Pemlimogene merolisbac (Aduro Biotech/Jannsen Biotech) |
ADU-214; JNJ-64041757 |
Phase 2 Clinical |
Aduro Biotech |
Ovarian Neoplasms; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung |
Details
|
Varlitinib Ditosylate |
QBT-01; ARRY-543; SPS-4370; ASLAN-001; ARRY-334543 |
Phase 3 Clinical |
Array Biopharma |
Biliary Tract Neoplasms; Neoplasms; Pancreatic Neoplasms; Bile Duct Neoplasms |
Details
|
Anti-EGFR CAR T-cell therapy (Seattle Children's Hospital) |
EGFR-806 |
Phase 1 Clinical |
Seattle Children'S Hospital |
Central Nervous System Neoplasms |
Details
|
YK-029A |
YK-029A |
Phase 1 Clinical |
Hainan Yuekang Biomedicine Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
MP-0274 |
DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 |
Phase 1 Clinical |
Molecular Partners Ag |
Neoplasms |
Details
|
Cetuximab biosimilar (Enzene Biosciences) |
|
Clinical |
Enzene Biosciences |
Carcinoma, Squamous Cell |
Details
|
BCA-101 |
BCA-101 |
Phase 1 Clinical |
Bicara Therapeutics |
Anus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Uveal melanoma; Chordoma; Colorectal Neoplasms; Carcinoma, Squamous Cell |
Details
|
Recombinant anti-InE monoclonal antibody |
|
Phase 1 Clinical |
Dingfu Biotarget Co Ltd |
Solid tumours |
Details
|
Anti-EGFR CAR-T cell therapy (Cellular Biomedicine Group) |
|
Phase 2 Clinical |
Cellular Biomedicine (Shanghai) Co Ltd, People'S Liberation Army General Hospital Military Service |
Neoplasms |
Details
|
TQB-3456 |
TQB-3456 |
Phase 1 Clinical |
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Centaurus Biopharma Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
Recombinant chimeric anti-EGFR monoclonal antibody (Qilu Pharmaceutical) |
QL-1105 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours |
Details
|
Betatinib |
TL-512 |
Phase 1 Clinical |
Aspedia Llc, Suzhou Teligene Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
Nazartinib |
EGF-816; EGFRmut-TKI EGF816 |
Phase 2 Clinical |
Novartis Pharma Ag |
Triple Negative Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma |
Details
|
Panitumumab-IRDye800CW (Stanford University) |
|
Phase 2 Clinical |
Stanford University |
Brain Neoplasms |
Details
|
QL1203 |
QL-1203 |
Phase 3 Clinical |
Qilu Pharmaceutical Co Ltd |
Colorectal Neoplasms |
Details
|
YZJ-0318 Maleate |
YZJ-0318 Maleate |
Phase 1 Clinical |
Shanghai Haiyan Trading Co Ltd, Yangtze River Pharmaceutical Group Jiangsu Haici Biological Pharmaceutical Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
Mefatinib |
|
Phase 3 Clinical |
Suzhou Maitai Bio-Technology Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
C-005 |
C-005 |
Phase 1 Clinical |
Nanjing Galaxy Biopharma Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
Epitinib Succinate |
HMPL-813 |
Phase 1 Clinical |
Hutchison Medipharma Ltd |
Solid tumours; Glioblastoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Tomuzotuximab |
GT-MAB-5.2-GEX |
Phase 2 Clinical |
Glycotope |
Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Cetuximab biosimilar (Guilin Sanjin) |
CDP-1 |
Phase 1 Clinical |
Guilin Sanjin Pharmaceutical Co Ltd, Dragonboat Biopharmaceutical |
Solid tumours; Colorectal Neoplasms |
Details
|
Sapitinib |
AZD-8931 |
Phase 2 Clinical |
Astrazeneca Pharmaceutical Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis |
Details
|
GC-1118A |
GC-1118; GC-1118A |
Phase 2 Clinical |
Korean Green Cross Corp |
Solid tumours; Stomach Neoplasms; Glioblastoma; Colorectal Neoplasms; Neoplasm Metastasis |
Details
|
Cetuximab biosimilar (AMPO Biotechnology) |
|
Phase 3 Clinical |
Ampo Biotechnology Inc |
Colorectal Neoplasms |
Details
|
Cetuximab biosimilar (Shanghai Zhangjiang Biotechnology) |
STI-001; CMAB-009 |
Phase 3 Clinical |
Shanghai Zhangjiang Biotechnology Co Ltd |
Colorectal Neoplasms |
Details
|
4-1BBz CD19-Her2tG (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Neoplasms |
Details
|
TQB3804 |
TQB-3804 |
Phase 1 Clinical |
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd |
Solid tumours; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
[111In] Panitumumab |
|
Phase 1 Clinical |
Stanford University |
Head and Neck Neoplasms |
Details
|
Epertinib |
S-222611 |
Phase 2 Clinical |
Shionogi & Co Ltd |
Neoplasms |
Details
|
Immunomodulatory progenitor cell therapy (Celixir) |
|
Phase 3 Clinical |
Celixir |
Endomyocardial Fibrosis; Cardiomyopathies |
Details
|
Cimaglermin alfa |
CGF-2 |
Phase 1 Clinical |
Ludwig Institute For Cancer Research |
Heart Failure |
Details
|
DBPR-112 |
DBPR-112 |
Phase 1 Clinical |
National Health Research Institutes |
Head and Neck Neoplasms; Lung Neoplasms |
Details
|
Recombinant anti-EGFR chimeric antibody (Harbin Pharmaceutical) |
|
Phase 1 Clinical |
Harbin Pharmaceutical Group Holding Co Ltd |
Colorectal Neoplasms |
Details
|
C225-ILS-DOX |
C225-ILs-dox |
Phase 2 Clinical |
Universitaetsspitals Basel |
Breast Neoplasms |
Details
|
HER-1 vaccine (Center of Molecular Immunology) |
HER1-ECD; HER1-VSSP; HER-1-ECD-VSSP |
Phase 2 Clinical |
Center Of Molecular Immunology |
Neoplasms |
Details
|
Losatuxizumab vedotin |
ABBV221; ABBV-221 |
Phase 1 Clinical |
Abbvie Inc |
Neoplasms |
Details
|
WTS-004 |
WTS-004 |
Phase 1 Clinical |
Hangzhou Wutong Tree Pharmaceutical Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
BPI-15086 |
BPI-15000; BPI-15086 |
Phase 1 Clinical |
Betta Pharmaceuticals Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
KSP-QRH-E3-IRDye800 |
|
Phase 1 Clinical |
University Of Michigan |
Cholangiocarcinoma |
Details
|
Antibody-drug nanocell conjugates (EnGeneIC) |
EGFR-EDV-RRM1; EGFR-EDV-PLK; EGFR-EDV-Dox |
Phase 1 Clinical |
Engeneic |
Glioblastoma |
Details
|
Cetuximab I-131 (Pacific Meinuoke) |
|
Clinical |
Jiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd |
Colorectal Neoplasms |
Details
|
ES-072 |
ES-072 |
Phase 1 Clinical |
Zhejiang Bosheng Pharmaceutical Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
ABY-029 |
ABY-029 |
Phase 1 Clinical |
Dartmouth College, Affibody, Li-Cor Bioscience |
Glioma |
Details
|
EGFRvIII-CAR |
|
Phase 1 Clinical |
Duke University Medical Center |
Glioblastoma |
Details
|
AVID-100 |
AVID-100 |
Phase 2 Clinical |
Formation Biologics |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Breast Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
SPH1188-11 |
SPH1188-11 |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
Autologous EGFR-CAR T cells (Bio-gene) |
|
Phase 1 Clinical |
Sun Yat-Sen University, Guangzhou Bio-Gene Technology Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
Yinlitinib |
|
Phase 1 Clinical |
Hec Pharm Co Ltd |
Solid tumours |
Details
|
Cetuximab biosimilar (AlphaMab) |
KN-005 |
Phase 3 Clinical |
Suzhou Alphamab Co Ltd |
Head and Neck Neoplasms; Anus Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms |
Details
|
Double-deleted Vaccinia Virus Plus CD/ SMR |
JX-929; vvDD-CDSR |
Phase 1 Clinical |
Sillajen |
Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma |
Details
|
Futuximab/Modotuximab |
Sym-004; 992-and-1024 |
Phase 3 Clinical |
Symphogen |
Solid tumours; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms |
Details
|
Simotinib Hydrochloride |
AL-6802; SIM-6802 |
Phase 1 Clinical |
Jiangsu Xiansheng Pharmaceutical Co Ltd, Advenchen Laboratories |
Colonic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Entinostat/Erlotinib Hydrochloride |
|
Phase 2 Clinical |
Colorado State University Foundation, Syndax |
Carcinoma, Non-Small-Cell Lung |
Details
|
PLB-1004 |
PLB-1004 |
Phase 1 Clinical |
Beijing Anshi Biotechnology Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
ZSP0391 |
ZSP-0391 |
Phase 1 Clinical |
Wuxi Apptec Co Ltd, Guangdong Zhongsheng Pharmaceutical Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
Sirotinib Maleate |
XZP-5491 |
Phase 1 Clinical |
Shandong Xuanzhu Pharmaceutical Technology Co Ltd |
Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
ZZ-06 |
ZZ-06 |
Phase 1 Clinical |
Changchun Intellicrown Pharmaceutical Co Ltd |
Solid tumours |
Details
|
Humanized anti-EGFR monoclonal antibody (Hualan Biological Engineering/Henan shengming biotechnology) |
|
Phase 2 Clinical |
Henan Shengming Biotechnology Research Institute Co Ltd, Hualan Genetic Engineering Co Ltd |
Colorectal Neoplasms |
Details
|
BB-101 (Blue Blood Biotech/National Cheng Kung University) |
BB-101 |
Phase 1 Clinical |
National Cheng Kung University, Blue Blood Biotech Corp |
Diabetic Foot |
Details
|
NRC-2694 |
NRC-2694; NRC-2694A; NRC-2694-A |
Phase 2 Clinical |
Natco |
Carcinoma, Squamous Cell |
Details
|
Tesevatinib |
KD-019; KD-020; XL-647; EXEL-7647 |
Phase 3 Clinical |
Exelixis Inc |
Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Carcinoma, Non-Small-Cell Lung; Polycystic Kidney, Autosomal Recessive; Neoplasm Metastasis |
Details
|
Selatinib Ditosilate |
QLNC-120 |
Phase 2 Clinical |
Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd |
Stomach Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
PB-357 |
PB-357 |
Phase 1 Clinical |
Pfizer Inc |
Neoplasms |
Details
|
BBT-176 |
BBT-176 |
Phase 2 Clinical |
Bridge Biotherapeutics |
Carcinoma, Non-Small-Cell Lung |
Details
|
Neptinib Di-P-methylbenzenesulfonate |
|
Phase 1 Clinical |
Shenzhen Neptunus Pharmaceutical Research Institute Co Ltd |
Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
JRF-103 |
JRF103; JRF-103 |
Phase 2 Clinical |
Shenzhen Jinrui Foundation Biotechnology Co Ltd |
Solid tumours |
Details
|
Recombinant anti-EGFR monoclonal antibody (Humanwell Healthcare) |
|
Phase 1 Clinical |
Humanwell Healthcare (Group) Co Ltd |
Colorectal Neoplasms |
Details
|
E-EDV-D682 |
PNU-15982; E-EDV-D682; EGFR-EDV-PNU-15982 |
Phase 2 Clinical |
Engeneic |
Pancreatic Neoplasms |
Details
|
MM-151 |
MM-151 |
Phase 2 Clinical |
Merrimack |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Allitinib Tosylate |
AST-6; ALS-1306; AST-1306 |
Phase 2 Clinical |
Shanghai Allist Pharmaceutical Technology Co Ltd |
Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Cetuximab biobetter (Mabtech/Sorrento) |
STI-001 |
Phase 3 Clinical |
Taizhou Maibo Taike Biotechnology Co Ltd, Shanghai Biomabs Pharmaceuticals Co Ltd |
Colorectal Neoplasms |
Details
|
Recombinant human anti-EGFR mAb (Serum Biotechnology) |
SY-101 |
Phase 2 Clinical |
Institute Of Bioengineering Chinese Academy Of Military Medical Sciences, Shanghai Serum Bio-Technology Co Ltd |
Solid tumours; Colorectal Neoplasms |
Details
|
Anti-EGFR CAR-T cell therapy (Beijing Pregene) |
|
Phase 2 Clinical |
Shenzhen Prekin Biopharmaceutical Co Ltd |
Colorectal Neoplasms |
Details
|
M-1231 |
M-1231 |
Phase 1 Clinical |
Emd Serono Research & Development Institute Inc, Merck Serono |
Solid tumours; Esophageal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) |
CPGJ-602; 602; CPGJ602; CPGJ 602 |
Phase 2 Clinical |
Shanghai Cp Guojian Pharmaceutical Co Ltd |
Colorectal Neoplasms |
Details
|
Recombinant chimeric anti-EGFR monoclonal antibody (Zhejiang Xinwei Shengke Biotechnology) |
|
Phase 1 Clinical |
Zhejiang Xinweishengke Biotechnology Co Ltd |
Esophageal Neoplasms |
Details
|
Cetuximab biosimilar (Kelun Group) |
KLA140; KL-A140 |
Phase 3 Clinical |
Sichuan Kelun Pharmaceutical Co Ltd |
Colorectal Neoplasms |
Details
|
TQ-B3395 |
TQ-B3395; TQ-B-3395 |
Phase 1 Clinical |
Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd |
Esophageal Neoplasms; Breast Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
[89Zr]Panitumumab (University of Alabama at Birmingham) |
|
Phase 2 Clinical |
University Of Alabama At Birmingham |
Colonic Neoplasms |
Details
|
LY-01010 |
LY-01010 |
Phase 1 Clinical |
Luye Pharma Group Ltd |
Breast Neoplasms |
Details
|
KY-1701 |
KY-1701 |
Phase 1 Clinical |
Jiangsu Kanion Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
BB-401 |
BB-401 |
Phase 2 Clinical |
Benitec Biopharma |
Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck |
Details
|
BPI-361175 |
BPI-361175 |
Phase 1 Clinical |
Betta Pharmaceuticals Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
Hemay-020 |
Hemay-020 |
Phase 1 Clinical |
Tianjin Hemay Pharmaceutical Co Ltd, Hainan General Sanyang Pharmaceutical Co Ltd |
Solid tumours; Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Serclutamab talirine |
ABBV-321 |
Phase 1 Clinical |
Abbvie Inc |
Neoplasms |
Details
|
JFAN-1001 |
JFAN-1001 |
Phase 2 Clinical |
Zhejiang Jianfeng Pharmaceutical Macutical Holdings |
Carcinoma, Non-Small-Cell Lung |
Details
|
FCN-411 |
FCN-411 |
Phase 1 Clinical |
Shanghai Fosun Pharmaceutical (Group) Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
Doxitinib mesylate |
|
Phase 2 Clinical |
Henan Real Biotechnology Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
Lifirafenib |
BGB-283; BeiGene-283 |
Phase 2 Clinical |
Beigene Ltd |
Solid tumours |
Details
|
EGFR IL12 CART |
|
Phase 1 Clinical |
Shenzhen Prekin Biopharmaceutical Co Ltd |
Colorectal Neoplasms |
Details
|
HA121-28 |
HA121-28; SYHA121-28 |
Phase 3 Clinical |
Cspc Pharmaceutical Technology (Shijiazhuang) Co Ltd |
Solid tumours; Biliary Tract Neoplasms; Medullary thyroid cancer (MTC); Bile Duct Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Olafertinib |
CK-101; RX-518; CS-2481; EGFR-IN-3 |
Phase 3 Clinical |
Suzhou Neupharma Co Ltd |
Lung Diseases; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma |
Details
|
AP-L1898 |
AP-L1898; JS111 |
Phase 2 Clinical |
Wigen Biomedicine technology (Shanghai) Co Ltd, Shanghai Junshi Biosciences Co Ltd, Suzhou Junjing Biomedical Technology Co Ltd |
Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
FHND-9041 |
FHND-9041 |
Phase 3 Clinical |
Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
CART-EGFR-IL13Ra2 |
CART-EGFR-IL13Ra2; CAR-T-EGFR-IL-13-Ra-2 |
Phase 1 Clinical |
University Of Pennsylvania |
Glioblastoma |
Details
|
BNA-035 |
BNA-035 |
Phase 1 Clinical |
Binacea Pharma Inc |
Solid tumours |
Details
|
EG-007 |
EG-007 |
Phase 3 Clinical |
Evergreen Therapeutics Inc |
Endometrial Neoplasms |
Details
|
SI-B001 |
SI-B001 |
Phase 3 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms, Glandular and Epithelial; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
JMT101 |
JMT-101 |
Phase 3 Clinical |
Shanghai Jinmante Biological Technology Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
Lazertinib |
GNS-1480; JNJ-1937; YH-25448; JNJ-73841937 |
Phase 3 Clinical |
Genosco |
Hepatic Insufficiency; Carcinoma, Non-Small-Cell Lung |
Details
|
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Solid tumours |
Details
|
Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center) |
|
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center |
Pancreatic Neoplasms |
Details
|
Durvalumab/Gefitinib |
|
Phase 2 Clinical |
Medimmune |
Carcinoma, Non-Small-Cell Lung |
Details
|
SKLB-1028 |
SKLB-1028 |
Phase 3 Clinical |
Sichuan University, CSPC Pharmaceutical Group Ltd |
Solid tumours; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid, Acute |
Details
|
SMET-12 |
SMET-12 |
Phase 1 Clinical |
Zhejiang Shimai Pharmaceutical Co Ltd |
Solid tumours |
Details
|
Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute) |
|
Phase 2 Clinical |
Barbara Ann Karmanos Cancer Institute, University Of Virginia |
Glioblastoma; Pancreatic Neoplasms |
Details
|
CKD-702 |
|
Phase 1 Clinical |
Chong Kun Dang Pharmaceutical Corp |
Carcinoma, Non-Small-Cell Lung |
Details
|
AFM-24 |
AFM-24 |
Phase 2 Clinical |
Affimed |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
Cetuximab biosimilar (Shanghai Henlius Biotech) |
HLX-05; JZB-29; JZB-28 |
Phase 1 Clinical |
Shanghai Henlius Biotech Co Ltd |
Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms |
Details
|
LR-004 |
LR-004; SYN-004 |
Phase 2 Clinical |
Lonn Ryonn Pharma Ltd |
Solid tumours; Carcinoma; Lymphoma, Large B-Cell, Diffuse; Graft vs Host Disease; Colorectal Neoplasms |
Details
|
Petosemtamab |
MCLA-158 |
Phase 1 Clinical |
Merus |
Colorectal Neoplasms |
Details
|
TAS-6417 |
CLN-081; TAS-6417 |
Phase 2 Clinical |
|
Carcinoma, Non-Small-Cell Lung |
Details
|
XZP-5209 |
XZP-5209 |
Phase 1 Clinical |
Xuanzhu (Shijiazhuang) Biotechnology Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
TY-9591 |
TY-9591 |
Phase 2 Clinical |
Zhejiang Tongkang Medicine Co Ltd |
Meningeal Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung |
Details
|
HLX-35 |
HLX-35 |
Phase 1 Clinical |
Shanghai Henlius Biologics Co Ltd |
Solid tumours |
Details
|
BEBT-109 |
BEBT-109 |
Phase 2 Clinical |
|
Carcinoma, Non-Small-Cell Lung |
Details
|
MRG003 |
MRG-003 |
Phase 2 Clinical |
Shanghai Miracogen Inc |
Biliary Tract Neoplasms; Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
ABBV-637 |
ABBV-637 |
Phase 1 Clinical |
Abbvie Inc |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
BAY-2927088 |
BAY-2927088; BAY2927088 |
Phase 1 Clinical |
Bayer Healthcare Company Ltd, Bayer Ag |
Carcinoma, Non-Small-Cell Lung |
Details
|
BDTX-1535 |
BDTX-1535 |
Phase 1 Clinical |
Black Diamond Therapeutics |
Glioblastoma; Carcinoma, Non-Small-Cell Lung |
Details
|
ZN-e4 |
ZN-e4; KP-673 |
Phase 2 Clinical |
Zentalis Pharmaceuticals, Zeno Pharma |
Carcinoma, Non-Small-Cell Lung |
Details
|
Sutetinib Maleate |
|
Phase 2 Clinical |
Jiangsu Maidu Pharmaceutical R & D Co Ltd, Jiangsu Suzhong Pharma Group Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
FWD1509 MsOH |
FWD1509 MsOH |
Phase 2 Clinical |
Shenzhen Forward Pharmaceuticals Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
BL-B01D1 |
|
Phase 1 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Neoplasms, Fibroepithelial; Solid tumours; Digestive System Neoplasms; Urologic Neoplasms |
Details
|
Demupitamab |
SCT-200 |
Phase 2 Clinical |
SinoCelltech Ltd |
Solid tumours; Head and Neck Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; Carcinoma; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
CX-904 |
CX-904 |
Phase 1 Clinical |
Amgen Inc, Cytomx Therapeutics |
Neoplasms |
Details
|
REGN-7075 |
REGN-7075 |
Phase 2 Clinical |
Regeneron Pharmaceuticals |
Solid tumours |
Details
|
TAK-186 |
EGFR x CD3 COBRA; MVC-101; TAK-186 |
Phase 2 Clinical |
Takeda Pharmaceutical Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
BC-3448 |
BC-3448; BC3448 |
Phase 1 Clinical |
Wuxi Zhikang Hongyi Biological Technology Co Ltd |
Solid tumours |
Details
|
Sunvozertinib |
DZD-9008 |
Phase 2 Clinical |
Dizal (Jiangsu) Pharmaceutical Co Ltd |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung |
Details
|
Pirotinib Hydrochloride |
KBP-5209 |
Phase 2 Clinical |
Shandong Xuanzhu Pharmaceutical Technology Co Ltd |
Solid tumours; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Bafisontamab |
EMB-01 |
Phase 2 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Biliary Tract Neoplasms; Liver Neoplasms; Stomach Neoplasms; Carcinoid Tumor; Digestive System Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular; Neoplasm Metastasis; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
ERAS-801 |
ERAS-801 |
Phase 1 Clinical |
Regents Of The University Of California |
Glioblastoma |
Details
|
BB-1705 |
BB-1705 |
Phase 2 Clinical |
Baili Sikang Biomedicine (Hangzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
BDTX-189 |
BDTX-189 |
Phase 2 Clinical |
Black Diamond Therapeutics |
Solid tumours |
Details
|
Kenaitinib |
MED-1007; TL-007 |
Phase 2 Clinical |
Jiangsu Maidu Pharmaceutical R & D Co Ltd |
Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Brain metastases; Carcinoma, Non-Small-Cell Lung |
Details
|
Imgatuzumab |
GA-201; R-7160; RG-7160; RO-5083945 |
Phase 2 Clinical |
Glycart Biotechnology |
Head and Neck Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
BLU-701 |
BLU-701; BLU 701 |
Phase 2 Clinical |
Blueprint Medicines |
Carcinoma, Bronchogenic; Carcinoma; Thoracic Neoplasms; Bronchial Neoplasms; Lung Diseases; Respiratory Tract Neoplasms; Neoplasms, Nerve Tissue; Lung Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Larotinib Mesylate |
Z-650 |
Phase 3 Clinical |
Guangdong Dongyangguang Pharmaceutical Co Ltd |
Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma |
Details
|
Pimurutamab |
HLX-07 |
Phase 2 Clinical |
Shanghai Henlius Biotech Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
BLU-945 |
BLU-945 |
Phase 2 Clinical |
Blueprint Medicines |
Carcinoma, Bronchogenic; Thoracic Neoplasms; Carcinoma; Bronchial Neoplasms; Lung Diseases; Respiratory Tract Neoplasms; Neoplasms, Nerve Tissue; Lung Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|